Encompass Health Corporation (NYSE:EHC) Stock Position Raised by Braun Stacey Associates Inc.

Braun Stacey Associates Inc. increased its stake in shares of Encompass Health Corporation (NYSE:EHC - Free Report) by 17.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 123,205 shares of the company's stock after purchasing an additional 18,298 shares during the quarter. Braun Stacey Associates Inc. owned approximately 0.12% of Encompass Health worth $12,478,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. US Bancorp DE boosted its stake in Encompass Health by 9.6% in the 4th quarter. US Bancorp DE now owns 1,380 shares of the company's stock worth $127,000 after buying an additional 121 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Encompass Health by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 644,764 shares of the company's stock valued at $59,544,000 after buying an additional 4,345 shares during the period. Arizona State Retirement System grew its stake in shares of Encompass Health by 0.7% during the 4th quarter. Arizona State Retirement System now owns 29,204 shares of the company's stock valued at $2,697,000 after buying an additional 212 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Encompass Health during the 4th quarter valued at $77,944,000. Finally, Jackson Creek Investment Advisors LLC grew its stake in shares of Encompass Health by 4.2% during the 4th quarter. Jackson Creek Investment Advisors LLC now owns 11,987 shares of the company's stock valued at $1,107,000 after buying an additional 484 shares during the period. Hedge funds and other institutional investors own 97.25% of the company's stock.

Insider Buying and Selling at Encompass Health

In other Encompass Health news, insider Elissa Joy Charbonneau sold 4,279 shares of the company's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $116.61, for a total value of $498,974.19. Following the transaction, the insider directly owned 11,958 shares of the company's stock, valued at $1,394,422.38. This represents a 26.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Mark J. Tarr sold 118,384 shares of the company's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $121.53, for a total value of $14,387,207.52. Following the completion of the transaction, the chief executive officer directly owned 527,070 shares in the company, valued at approximately $64,054,817.10. The trade was a 18.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 132,663 shares of company stock valued at $16,034,082 in the last three months. Corporate insiders own 2.10% of the company's stock.

Encompass Health Stock Down 1.1%

EHC stock traded down $1.33 during trading on Tuesday, reaching $118.06. The stock had a trading volume of 877,676 shares, compared to its average volume of 703,065. Encompass Health Corporation has a 1-year low of $82.74 and a 1-year high of $123.13. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.81. The company has a market capitalization of $11.90 billion, a P/E ratio of 24.39, a PEG ratio of 2.42 and a beta of 0.88. The firm has a fifty day moving average price of $119.46 and a 200 day moving average price of $105.70.

Encompass Health (NYSE:EHC - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.19 by $0.18. Encompass Health had a return on equity of 17.63% and a net margin of 8.97%. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. During the same period in the prior year, the company posted $1.12 EPS. Encompass Health's quarterly revenue was up 10.6% on a year-over-year basis. On average, equities analysts anticipate that Encompass Health Corporation will post 4.8 earnings per share for the current year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st will be given a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date is Tuesday, July 1st. Encompass Health's payout ratio is 14.05%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on EHC. UBS Group boosted their price objective on shares of Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a research note on Monday, April 28th. Barclays lifted their price objective on Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Wall Street Zen lowered Encompass Health from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. KeyCorp lifted their price objective on Encompass Health from $122.00 to $135.00 and gave the company an "overweight" rating in a research note on Tuesday, May 27th. Finally, Royal Bank Of Canada lifted their price objective on Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a research note on Monday, April 28th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $127.00.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.